Lucid Diagnostics Inc. Q2 FY2025 earnings call

• The upcoming LCD-CAC meeting is a key milestone for securing positive Medicare coverage, with the company seeing it as a strong indicator of progress. - EsoGuard test volume for Q2 was 2,756 tests, within target range, with revenue at $1.2 million, a 40% increase from Q1. - Partnered with Hoag, a large health system, to launch a comprehensive EsoGuard esophageal precancer testing program system-wide. - Strengthened balance sheet with an underwritten public offering in the past quarter, netting $16.1 million in proceeds. - Publication in the American Journal of Gastroenterology of a pilot study on EsoGuard, with ongoing NIH-funded 5-year study. - Positioning resources to accelerate commercialization once Medicare coverage is secured.

The EsoGuard product segment had a second quarter test volume of 2,756 tests, within the target range of 2,500 to 3,000 tests per quarter. Revenue was $1.2 million, a 40% increase from the first quarter and matching the previous quarterly high. The segment's financial performance is centered around EsoGuard's test volume and revenue growth.

• Anticipates a positive outcome from the upcoming CAC meeting and believes Medicare coverage is imminent. - Already taking proactive steps to accelerate EsoGuard's commercialization once Medicare coverage is secured. - Ongoing market access efforts with commercial payers, expecting to secure additional positive coverage policies before final Medicare process completion. - Concierge and contracting pipeline expected to yield tangible results in coming quarters.

Forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from statements made. Factors are described in the company's filings with the SEC, including Part I, Item 1A entitled Risk Factors in the most recent annual report on Form 10-K and subsequent updates.

Q: Mark Massaro asked about the timing of the draft LCD after the CAC meeting and expectations for final LCD.

A: Lishan Aklog explained the sequence of CAC meeting, draft LCD publication, comment period, and final LCD, expecting a draft soon after the CAC meeting and final LCD to follow with a reasonable timeline.

Q: Anthony Vendetti inquired about commercial pipeline and timing after CAC meeting.

A: Lishan Aklog discussed positive conversations with commercial payers, progress with Highmark, and expectations of securing more regional and national commercial coverage policies.

Q: Mike Matson asked about feedback from CAC meeting and impact on payment amount.

A: Lishan Aklog stated the CAC meeting is about coverage, not payment amount, which is handled separately.

Q: Ross Osborn asked about Hoag partnership details and business model margin.

A: Lishan Aklog detailed the multidisciplinary Hoag partnership and Dennis McGrath explained the business model with high contribution margins from EsoGuard tests.